Form 8-K · Current Report · Filed 2026-02-12
DexCom Reports Strong 2025 Financial Results and Strategic Achievements
DexCom, Inc. reported robust financial results for the quarter and fiscal year ended December 31, 2025, with worldwide revenue growing 13% year-over-year to $1.260 billion in Q4 2025 and 16% year-over-year to $4.662 billion for the full year 2025. The company also highlighted strategic achievements, including the launch of the Dexcom G7 15 Day CGM system in the United States, FDA clearance for Dexcom Smart Basal, and expanded access to Dexcom CGM in Quebec. DexCom provided fiscal year 2026 guidance, reiterating revenue expectations of approximately 11-13% growth and establishing Adjusted EBITDA Margin guidance at approximately 30-31%.
- Filer
- Dexcom Inc. DXCM · NASDAQ
- Filed
- Accession
- 0001093557-26-000025
- CIK
- 0001093557
- Signal
- Medium impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Reported Item
Market reaction
Close before filing
$68.15
Next session
+2.7%
Since filing
+22.5%
Latest close
$83.45
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from DXCM reporting the same item, with the next session's move:
About Dexcom Inc.
Dexcom Inc. is a prominent player in the medical technology sector, specializing in continuous glucose monitoring (CGM) systems for diabetes management. The company's primary function is to develop and distribute innovative CGM devices that provide real-time glucose readings, allowing individuals with diabetes to make informed decisions about their health. Dexcom’s products play a critical role in healthcare by offering an alternative to traditional fingerstick testing, thus improving quality of life for many users. The company impacts several sectors, most notably within healthcare and technology, by integrating advanced data analytics and wireless technology into its monitoring systems. This not only aids individuals in managing their glucose levels but also supports healthcare providers in delivering better patient care through data-driven insights. In the financial market, Dexcom Inc. is recognized for its contributions to the growing field of digital health solutions. The company has established itself as a leader in its niche, continuously pushing the boundaries of technology to offer more precise and user-friendly glucose monitoring options. Founded in 1999 and headquartered in San Diego, California, Dexcom remains at the forefront of diabetes management solutions.
Never miss another DXCM filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.